Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Maravai LifeSciences Holdings had a gross margin of 51.19% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Maravai LifeSciences Holdings Gross Margin % Related Terms
Maravai LifeSciences Holdings Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MRVI vs LBRX, SLDB, JANX: Gross Margin % Comparison
For the Biotechnology subindustry, Maravai LifeSciences Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maravai LifeSciences Holdings Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Maravai LifeSciences Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Maravai LifeSciences Holdings (MEX:MRVI) has a Gross Margin % of 51.19% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Maravai LifeSciences Holdings and its competitors. This is near median its historical median of 52.12. Over the past decade, Maravai LifeSciences Holdings' Gross Margin % has ranged from 18.30 to 82.41. According to the industry distribution chart, Maravai LifeSciences Holdings ranks #563 out of 735 companies in the Biotechnology industry, placing it in the top 76.6%.
Is Maravai LifeSciences Holdings' Gross Margin % too high?
Maravai LifeSciences Holdings' current Gross Margin % of 51.19% is near median its 10-year median of 52.12. Over the past 10 years, this metric has ranged from a low of 18.30 to a high of 82.41. The Biotechnology industry median Gross Margin % is 60.90. Maravai LifeSciences Holdings' value of 51.19% is 15.9% below this industry median. Based on the distribution chart, Maravai LifeSciences Holdings ranks #563 out of 735 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Maravai LifeSciences Holdings has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Maravai LifeSciences Holdings' Gross Margin % compare to LBRX and SLDB?
According to the Biotechnology industry distribution chart, Maravai LifeSciences Holdings ranks #563 out of 735 companies for Gross Margin %. This places Maravai LifeSciences Holdings in the lower half of its industry. The industry median Gross Margin % is 60.90. Maravai LifeSciences Holdings' value of 51.19% is 15.9% below this benchmark. Historically, Maravai LifeSciences Holdings' own Gross Margin % has ranged from 18.30 to 82.41 over the past decade. While the company's 10-year median is 52.12 vs. the industry median of 60.90, Maravai LifeSciences Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maravai LifeSciences Holdings's current Gross Margin % of 51.19% is 15.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Maravai LifeSciences Holdings and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maravai LifeSciences Holdings's current Gross Margin % is 51.19%, which is near median its own 10-year median of 52.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maravai LifeSciences Holdings stock overvalued right now?
Maravai LifeSciences Holdings (MEX:MRVI) has a current Gross Margin % of 51.19%. The stock's GF Value™ is MXN52.37, compared to a current price of MXN85.00 — trading 62.3% above its estimated fair value. The current Gross Margin % is 51.19%, which is near median its 10-year median of 52.12 and 15.9% below the Biotechnology industry median of 60.90. Maravai LifeSciences Holdings' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Maravai LifeSciences Holdings (MEX:MRVI), the current Gross Margin % is 51.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maravai LifeSciences Holdings (MEX:MRVI) Overvalued in 2026?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued.
The current stock price of MXN85.00 is trading 62.3% above its estimated GF Value™ of MXN52.37.
Key valuation signals for MEX:MRVI:
Gross Margin %: 51.19% (near median its 10-year median of 52.12)
GF Value™: MXN52.37 vs. price of MXN85.00 (62.3% above fair value)
Industry Position: 15.9% below the Biotechnology median (#563 of 735)
No single metric tells the full story. See the MEX:MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maravai LifeSciences Holdings Business Description
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
62GF Score
Get the complete analysis for MEX:MRVI
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MRVI has been successfully added to your 
